Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 ...
Nurix Therapeutics' NX-5948, a BTK degrader, received FDA Fast Track designation for treating r/r CLL/SLL after positive Phase 1 data. The drug showed clinical benefits and was well-tolerated in trials, with plans to accelerate enrollment for a pivotal study.
Related Clinical Trials
Reference News
Nurix Therapeutics' NX-5948, a BTK degrader, received FDA Fast Track designation for treating r/r CLL/SLL after positive Phase 1 data. The drug showed clinical benefits and was well-tolerated in trials, with plans to accelerate enrollment for a pivotal study.
Nurix Therapeutics received FDA Fast Track designation for NX-5948, a BTK degrader, for treating relapsed or refractory CLL/SLL. Positive Phase 1 trial data showed clinical benefits and tolerability. Nurix plans to accelerate enrollment for a pivotal study, aiming for rapid development and review under Fast Track.